Dinsesh V.  Patel net worth and biography

Dinsesh Patel Biography and Net Worth

Dr. Dinesh V. Patel Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Patel has served as a member of the Company's Board and as the Company's President and Chief Executive Officer since December 2008. Dr. Patel has more than 35 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining the Company, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on the development of novel drugs for metabolic syndrome. Prior to that, he was President, Chief Executive Officer and Co-Founder of Miikana Therapeutics, an oncology-based company, from 2003 until it was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was acquired by Pfizer in 2005), from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Prior to Vicuron, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India. The Company believes that because of his expertise, extensive knowledge of the Company and experience as an executive officer of biotechnology companies, Dr. Patel is able to make valuable contributions to the Board.

What is Dinsesh V. Patel's net worth?

The estimated net worth of Dinsesh V. Patel is at least $45.46 million as of July 25th, 2025. Dr. Patel owns 520,603 shares of Protagonist Therapeutics stock worth more than $45,464,260 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Patel may own. Learn More about Dinsesh V. Patel's net worth.

How do I contact Dinsesh V. Patel?

The corporate mailing address for Dr. Patel and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on Dinsesh V. Patel's contact information.

Has Dinsesh V. Patel been buying or selling shares of Protagonist Therapeutics?

Dinsesh V. Patel has not been actively trading shares of Protagonist Therapeutics during the last ninety days. Most recently, Dinesh V. Ph D. Patel sold 10,415 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $54.78, for a transaction totalling $570,533.70. Following the completion of the sale, the chief executive officer now directly owns 520,603 shares of the company's stock, valued at $28,518,632.34. Learn More on Dinsesh V. Patel's trading history.

Who are Protagonist Therapeutics' active insiders?

Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Arturo Molina (Chief Medical Officer), Dinsesh Patel (CEO), and William Waddill (Director). Learn More on Protagonist Therapeutics' active insiders.

Are insiders buying or selling shares of Protagonist Therapeutics?

In the last year, insiders at the sold shares 13 times. They sold a total of 159,391 shares worth more than $9,160,103.66. The most recent insider tranaction occured on October, 10th when Director William D Waddill sold 12,000 shares worth more than $979,440.00. Insiders at Protagonist Therapeutics own 4.9% of the company. Learn More about insider trades at Protagonist Therapeutics.

Information on this page was last updated on 10/10/2025.

Dinsesh V. Patel Insider Trading History at Protagonist Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2025Sell10,415$54.78$570,533.70520,603View SEC Filing Icon  
7/23/2025Sell17,520$54.79$959,920.80531,018View SEC Filing Icon  
7/22/2025Sell22,065$55.05$1,214,678.25548,538View SEC Filing Icon  
7/21/2025Sell12,859$54.86$705,444.74570,603View SEC Filing Icon  
2/19/2025Sell5,359$38.18$204,606.62540,260View SEC Filing Icon  
11/25/2024Sell78,520$46.96$3,687,299.20435,208View SEC Filing Icon  
6/7/2024Sell35,000$35.19$1,231,650.00515,415View SEC Filing Icon  
4/1/2024Sell25,000$28.31$707,750.00549,590View SEC Filing Icon  
3/1/2024Sell30,000$31.62$948,600.00574,590View SEC Filing Icon  
12/21/2021Sell15,000$32.14$482,100.00View SEC Filing Icon  
1/19/2021Sell24,846$24.60$611,211.60450,990View SEC Filing Icon  
8/6/2019Sell10,792$8.85$95,509.20View SEC Filing Icon  
3/1/2019Sell2,183$8.03$17,529.49386,014View SEC Filing Icon  
2/6/2019Sell10,909$7.74$84,435.66367,396View SEC Filing Icon  
12/20/2017Sell1,790$19.55$34,994.50192,227View SEC Filing Icon  
See Full Table

Dinsesh V. Patel Buying and Selling Activity at Protagonist Therapeutics

This chart shows Dinesh V Ph D Patel's buying and selling at Protagonist Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Protagonist Therapeutics Company Overview

Protagonist Therapeutics logo
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More

Today's Range

Now: $87.33
Low: $85.13
High: $88.10

50 Day Range

MA: $78.32
Low: $64.00
High: $90.07

2 Week Range

Now: $87.33
Low: $33.70
High: $93.25

Volume

736,770 shs

Average Volume

862,927 shs

Market Capitalization

$5.46 billion

P/E Ratio

140.86

Dividend Yield

N/A

Beta

2.19